CD8A and melanoma: Additionally, intratumoral delivery of TORC2-deficient DC delays melanoma progression in a CD8+ T cell-dependent manner (14), whereas skin grafts from donors lacking TORC2 in DC undergo enhanced CD8+ T cell-mediated rejection (15).